Haemonetics Corp. v. Baxter Healthcare Corp.

577 F. Supp. 2d 482, 2008 U.S. Dist. LEXIS 73764, 2008 WL 4330570
CourtDistrict Court, D. Massachusetts
DecidedSeptember 16, 2008
DocketCivil Action 05-12572-NMG
StatusPublished
Cited by1 cases

This text of 577 F. Supp. 2d 482 (Haemonetics Corp. v. Baxter Healthcare Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Haemonetics Corp. v. Baxter Healthcare Corp., 577 F. Supp. 2d 482, 2008 U.S. Dist. LEXIS 73764, 2008 WL 4330570 (D. Mass. 2008).

Opinion

MEMORANDUM & ORDER

GORTON, District Judge.

The defendant in a patent infringement action moves for summary judgment of non-infringement.

I. Background

The Plaintiff, Haemonetics Corp. (“Hae-monetics”), alleges that Baxter Healthcare Corp. (“Baxter”) has infringed and continues to infringe, directly, contributorily and/or by inducement, United States Patent No. 6,705,983 (hereinafter referred to as “the '983 patent”), a patent owned by Haemonetics. The '983 patent claims a centrifugal device used for separating and collecting components in a liquid such as blood. Haemonetics asserts that in or around 2003, Baxter began offering and selling a blood component collection system known as the Alyx System, which includes a centrifugal device, and that that the Alyx System infringes the '983 patent.

On March 27, 2007, the parties entered an assented to motion for joinder of Fen-wal Inc. (“Fenwal”) as a defendant in the action. Fenwal is an independent corporation formed upon Baxter’s complete divestiture of its transfusion therapies business, which includes the allegedly infringing device.

The parties appeared before this Court for a Markman hearing on July 24, 2007, and this Court construed the '983 Patent in a Memorandum and Order entered on August 16, 2007, 517 F.Supp.2d 514. That Order construed the '983 Patent to include, as separate elements:

1) First Drive Units means the assemblage of components responsible for rotating the tubes at an angular rate of o and does not include the tubes or vessel.
2) Second Drive Units means the assemblage of components responsible for rotating the centrifugal vessel (or centrifugal unit) at an angular rate of 2w and does not include the tubes or vessel.

Fenwal moves for partial summary judgment on the grounds that the Alyx system cannot infringe the '983 patent because it does not include a separate “second drive unit”. Although the centrifugal vessel of the Alyx system rotates at an angular rate of 2&> (i.e., twice the rate at which the tubes rotate), Fenwal alleges that it achieves that result in a completely differ *484 ent way from that taught by the '983 patent. Haemonetics counters that the accused device infringes the '983 patent under the doctrine of equivalents which Fen-wal also denies.

II. Analysis

A. Legal Standards

1.Summary Judgment Standard

The role of summary judgment is “to pierce the pleadings and to assess the proof in order to see whether there is a genuine need for trial.” Mesnick v. General Elec. Co., 950 F.2d 816, 822 (1st Cir.1991)(quoting Garside v. Osco Drug, Inc., 895 F.2d 46, 50 (1st Cir.1990)). The burden is upon the moving party to show, based upon the pleadings, discovery and affidavits, “that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law.” Fed.R.Civ.P. 56(c).

A fact is material if it “might affect the outcome of the suit under the governing law.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). “Factual disputes that are irrelevant or unnecessary will not be counted.” Id. A genuine issue of material fact exists where the evidence with respect to the material fact in dispute “is such that a reasonable jury could return a verdict for the nonmoving party.” Id.

Once the moving party has satisfied its burden, the burden shifts to the non-moving party to set forth specific facts showing that there is a genuine, triable issue. Celotex Corp. v. Catrett, 477 U.S. 317, 324, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). The Court must view the entire record in the light most hospitable to the non-moving party and indulge all reasonable inferences in that party’s favor. O’Connor v. Steeves, 994 F.2d 905, 907 (1st Cir.1993). If, after viewing the record in the non-moving party’s favor, the Court determines that no genuine issue of material fact exists and the moving party is entitled to judgment as a matter of law, summary judgment is appropriate.

2.Infringement Standard

A claim of patent infringement requires a two step analysis. First, the court must construe the asserted claim, as this Court did in its Memorandum and Order entered on August 16, 2007 (“the Markman order”). RF Del. Inc. v. Pac. Keystone Techs., Inc., 326 F.3d 1255, 1266 (Fed.Cir.2003). That construction is rendered as a matter of law. Second, it “must determine whether the accused product or process contains each limitation” of the claims, “either literally or by a substantial equivalent”. Id. The determination of whether all limitations are present is a question of fact, governed by the summary judgment standard discussed above.

3.The Doctrine of Equivalents

The doctrine of equivalents provides that

a product or process that does not literally infringe upon the express terms of a patent claim may nonetheless be found to infringe if there is “equivalence” between the elements of the accused product or process and the claimed elements of the patented invention.

Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 21, 117 S.Ct. 1040, 137 L.Ed.2d 146 (1997), citing Graver Tank & Mfg. Co. v. Linde Air Products Co., 339 U.S. 605, 70 S.Ct. 854, 94 L.Ed. 1097 (1950). It recognizes that if a patent could be contravened by the alteration of an insignificant detail it would offer no meaningful protection at all. Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 731, 122 S.Ct. 1831, 152 L.Ed.2d 944 (2002).

That doctrine is, of course, in tension with the public-notice and definitional *485 functions of patent claims and risks deterring non-infringing innovation as well as infringing behavior. See id. at 727, 122 S.Ct. 1881. In order to alleviate that tension, the doctrine of equivalents is bounded by several complementary rules of law.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Haemonetics Corp. v. Baxter Healthcare Corp.
593 F. Supp. 2d 298 (D. Massachusetts, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
577 F. Supp. 2d 482, 2008 U.S. Dist. LEXIS 73764, 2008 WL 4330570, Counsel Stack Legal Research, https://law.counselstack.com/opinion/haemonetics-corp-v-baxter-healthcare-corp-mad-2008.